EHAVE INC | 6-K: Report of foreign private issuer (related to financial reporting)

SECMay 21 16:18 ET · Announcements

Combatting The 'Bad Trip': New Research Project Seeks Solutions That Go Beyond Psychedelics

Benzinga Real-time NewsFeb 3, 2023 12:47 ET

Ehave Provides Progress Update on Its HPPD Study With University of Melbourne

GlobeNewswireFeb 2, 2023 08:36 ET

FDA Green Lights New Study Testing IV Ketamine Infusion For Depressive Disorder

Benzinga Real-time NewsDec 16, 2022 17:04 ET

Press Release: Ehave Shareholder From CEO Ben Kaplan and Corporate Update

Dow JonesDec 7, 2022 08:08 ET

Ehave Partners With Halugen Life Sciences To Create A Ketamine Precision Medicine Platform For Clinical Research

Benzinga Real-time NewsJun 1, 2022 16:30 ET